New Features in Screening of Retinopathy of Prematurity. Our Experience with New Recommendations for Retinopathy of Prematurity Screening
Czech and Slovak Ophthalmology · 30.05.2025
DOI: 10.31348/2025/23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Czech and Slovak Ophthalmology, online erschienen am 30.05.2025. Verfasst von Dana Tomčíková und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Retinopathy of Prematurity, Neonatal Screening.
Abstract (Originalsprache)
Retinopathy of prematurity (ROP) is always a serious and sight-threatening condition, and its treatable stages require early detection and adequate treatment. It is necessary to focus on the principles of screening of ROP and recurrences thereof, which occur more often with the onset of intravitreal treatment using anti-vascular endothelial growth factor (anti-VEGF) agents. In this study, we evaluate the recurrence of ROP after primary treatment with intravitreally administered bevacizumab or ranibizumab, its frequency and timing of occurrence. Also discussed are the rules for screening of ROP, its recurrence and the need for long-term follow-up monitoring of children with any form of ROP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
Tomčíková, D., Prepiaková, Z., Bušányová, B., & Kostolná, B. (2025). New Features in Screening of Retinopathy of Prematurity. Our Experience with New Recommendations for Retinopathy of Prematurity Screening. Czech and Slovak Ophthalmology. https://doi.org/10.31348/2025/23
Vancouver
Tomčíková D, Prepiaková Z, Bušányová B, Kostolná B. New Features in Screening of Retinopathy of Prematurity. Our Experience with New Recommendations for Retinopathy of Prematurity Screening. Czech and Slovak Ophthalmology. 2025. doi:10.31348/2025/23
BibTeX
@article{Tomkov2025,
author = {Tomčíková, Dana and Prepiaková, Zuzana and Bušányová, Beáta and Kostolná, Barbora},
title = {New Features in Screening of Retinopathy of Prematurity. Our Experience with New Recommendations for Retinopathy of Prematurity Screening},
journal = {Czech and Slovak Ophthalmology},
year = {2025},
doi = {10.31348/2025/23}
}
EUVIMED